Pulmonary Hypertension Trial, Recruiting NCT06512935 Sponsor: University of Alabama at Birmingham Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Pulmonary Hypertension Trial, Recruiting

NCT06512935
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Premature babies born before 34 weeks of pregnancy who had breathing difficulties at birth and are now recovering, and are currently on a breathing machine (either conventional mechanical ventilation or a type called high-frequency jet ventilation)
  • Babies who are older than 7 days but younger than 1 month of age at the time of joining the trial
  • Babies born at a pregnancy stage of between 21 and 34 weeks
  • Babies whose parent or legal guardian has given written permission for them to take part

Who may not be able to join:

  • Babies who have a confirmed blood infection (sepsis shown by a positive blood culture)
  • Babies born with physical conditions affecting how their lungs or airways work
  • Babies with certain types of serious heart conditions present from birth (cyanotic or ductal-dependent congenital heart disease)
  • Babies whose medical team considers them too unwell or unstable to safely take part in the trial
  • Babies who need medications to keep their heart pumping properly, or who are receiving steroids to support heart function
  • Babies who are on non-invasive breathing support (such as a mask or nasal prongs), or babies who have a serious chronic lung condition (bronchopulmonary dysplasia) combined with high blood pressure in the lungs
  • Babies who have open skin wounds or sores on their chest

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kulsajan S Bhatia, MD, University of Alabama at Birmingham

Phone: 9172149882

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2026
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in cardiac index with increase/decrease in PEEP as measured by ECHO and EIT; PEEP of best compliance and best oxygenation as per EIT measurements

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov